CliffBio
biologic

Jynneos

Smallpox and Mpox Vaccine, Live, Non-replicating

Loss of exclusivitySeptember 2031projected — 12-year biologic exclusivity estimate
CompanyBavarian Nordic A/S

Drug detail

Brand nameJynneos
Active ingredientSmallpox and Mpox Vaccine, Live, Non-replicating
Strength0.5-3.95 X 10E8 INF. U/.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2019
Marketing statusRx

More from Bavarian Nordic A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Jynneos patent cliff — loss of exclusivity September 2031 | CliffBio